文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

新生儿严重甲状旁腺功能亢进症:钙、PTH与CASR基因的新见解

Neonatal Severe Hyperparathyroidism: Novel Insights From Calcium, PTH, and the CASR Gene.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究对57例新生儿严重甲状旁腺功能亢进症(NSHPT)病例进行基因型/表型配对分析,发现CASR纯合变异者的血钙和PTH水平高于杂合变异者,且血钙高于4.5 mM仅见于纯合变异者(占该配对83%),该阈值有助于早期诊断和决定甲状旁腺切除术。

要点

  • NSHPT纯合变异者血钙和PTH水平高于杂合变异者。
  • 血钙高于4.5 mM仅见于纯合变异者,占该配对83%。
  • 血钙高于4.5 mM支持早期诊断CASR剂量并指导甲状旁腺切除术。

核心结论

  • 在NSHPT配对中,CASR致病性变异纯合者的血钙和PTH水平高于杂合者。
  • 血钙高于4.5 mM在NSHPT中常见且仅见于大多数纯合者,该阈值支持早期明确诊断CASR剂量。
  • 该阈值促进对大多数纯合者行确定性全甲状旁腺切除术。

研究设计与样本

  • 对57例新生儿严重甲状旁腺功能亢进症病例进行基因型/表型配对分析,每个病例需评估血钙、PTH、正常PTH上限和致病性CASR变异剂量。

主要发现

  • 纯合和杂合NSHPT是涉及CASR的9种基因型/表型配对中的2种。
  • 纯合CASR变异剂量通常比杂合更具侵袭性。
  • 杂合者中,体外高等级CASR变异比低等级变异在体内更具致病性。
  • 胎儿钙不足(如母体甲状旁腺功能减退症所致)引起胎儿继发性甲状旁腺功能亢进,在新生儿中持续且可逆。
  • NSHPT配对中,纯合者血钙和PTH高于杂合者。

关键数值与推荐

  • 极端高钙血症(高于4.5 mM;正常2.2-2.6 mM)是稳健的生物标志物,仅见于纯合者(占该配对83%),可发生于第一周。

临床怎么用

  • 血钙高于4.5 mM支持早期明确诊断CASR剂量,并促进对大多数纯合者行确定性全甲状旁腺切除术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Neonatal severe hyperparathyroidism (NSHPT) is rare and potentially lethal. It is usually from homozygous or heterozygous germline-inactivating CASR variant(s). NSHPT shows a puzzling range of serum calcium and parathyroid hormone (PTH) levels. Optimal therapy is unclear. EVIDENCE ACQUISITION: We categorized genotype/phenotype pairings related to CASRs. For the 2 pairings in NSHPT, each of 57 cases of neonatal severe hyperparathyroidism required calcium, PTH, upper normal PTH, and dosage of a germline pathogenic CASR variant. EVIDENCE SYNTHESIS: Homozygous and heterozygous NSHPT are 2 among a spectrum of 9 genotype/phenotype pairings relating to CASRs and NSHPT. For the 2 NSHPT pairings, expressions differ in CASR allelic dosage, CASR variant severity, and sufficiency of maternofetal calcium fluxes. Homozygous dosage of CASR variants was generally more aggressive than heterozygous. Among heterozygotes, high-grade CASR variants in vitro were more pathogenic in vivo than low-grade variants. Fetal calcium insufficiency as from maternal hypoparathyroidism caused fetal secondary hyperparathyroidism, which persisted and was reversible in neonates. Among NSHPT pairings, calcium and PTH were higher in CASR homozygotes than in heterozygotes. Extreme hypercalcemia (above 4.5 mM; normal 2.2-2.6 mM) is a robust biomarker, occurring only in homozygotes (83% of that pairing). It could occur during the first week. CONCLUSIONS: In NSHPT pairings, the homozygotes for pathogenic CASR variants show higher calcium and PTH levels than heterozygotes. Calcium levels above 4.5 mM among NSHPT are frequent and unique only to most homozygotes. This cutoff supports early and robust diagnosis of CASR dosage. Thereby, it promotes definitive total parathyroidectomy in most homozygotes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Marx SJ, Sinaii N. Neonatal Severe Hyperparathyroidism: Novel Insights From Calcium, PTH, and the CASR Gene. J Clin Endocrinol Metab. 2020. PMID: 31778168. doi:10.1210/clinem/dgz233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。